JAMES M. FRATES - 30 Dec 2022 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ James M. Frates
Issuer symbol
AMLX
Transactions as of
30 Dec 2022
Net transactions value
+$34,400
Form type
4
Filing time
04 Jan 2023, 20:33:55 UTC
Previous filing
17 Jun 2022
Next filing
10 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $34,400 +5,000 +16% $6.88 36,667 30 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.1% $0.000000 447,000 30 Dec 2022 Common Stock 5,000 $6.88 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter.